Literature DB >> 16784025

Phenoxodiol, a novel approach for the treatment of ovarian cancer.

Gil Mor1, Han-Hsuan Fu, Ayesha B Alvero.   

Abstract

Epithelial ovarian cancer is the fourth leading cause of cancer-related deaths in women and is the most lethal of the gynecological malignancies. Thle high mortality rate arises from difficulties in the early detection of the disease and the widespread development of chemoresistance. Phenoxodiol, a novel isoflavone derivative, has demonstrated antitumor activity. In addition, it has been shown to induce cell death in chemoresistant epithelial ovarian cancer cells. Moreover, suboptimal exposure of these cells to phenoxodiol lowered the IC50 value of numerous chemotherapeutic agents. In this review, the current understanding of the mechanism of action of phenoxodiol, its potential clinical application for the treatment of ovarian cancer and the concept of chemosensitization are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16784025

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  9 in total

Review 1.  Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Subhash Padhye
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

2.  The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.

Authors:  Harriet M Kluger; Mary M McCarthy; Ayesha B Alvero; Mario Sznol; Stephan Ariyan; Robert L Camp; David L Rimm; Gil Mor
Journal:  J Transl Med       Date:  2007-01-26       Impact factor: 5.531

3.  The continuing search for antitumor agents from higher plants.

Authors:  Li Pan; Heebyung Chai; A Douglas Kinghorn
Journal:  Phytochem Lett       Date:  2010-03-12       Impact factor: 1.679

4.  The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells.

Authors:  Patries M Herst; Joanne E Davis; Paul Neeson; Michael V Berridge; David S Ritchie
Journal:  Haematologica       Date:  2009-06-16       Impact factor: 9.941

5.  Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.

Authors:  Chen Yao; Sujia Wu; Dong Li; Huimin Ding; Zuyu Wang; Yongjiang Yang; Shichang Yan; Zhangping Gu
Journal:  Mol Oncol       Date:  2012-05-05       Impact factor: 6.603

6.  Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer.

Authors:  Jan B Howes; Paul L de Souza; Leanne West; Li Jiu Huang; Laurence G Howes
Journal:  BMC Clin Pharmacol       Date:  2011-02-03

7.  Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells.

Authors:  R A C McPherson; P T Galettis; P L de Souza
Journal:  Br J Cancer       Date:  2009-02-10       Impact factor: 7.640

8.  Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo.

Authors:  Sylvianna Georgaki; Margarita Skopeliti; Marinos Tsiatas; Katerina A Nicolaou; Kyriaki Ioannou; Alan Husband; Aristotelis Bamias; Meletios A Dimopoulos; Andreas I Constantinou; Ourania E Tsitsilonis
Journal:  J Cell Mol Med       Date:  2009-02-11       Impact factor: 5.310

9.  NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study.

Authors:  Koba Kiknavelidze; Mikheil Shavdia; Nana Chikhladze; Lia Abshilava; Marinella Messina; Gisela Mautner; Graham Kelly
Journal:  Curr Ther Res Clin Exp       Date:  2021-03-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.